Heat Biologics with ticker code (HTBX) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 40 and 20 and has a mean target at 29.25. Given that the stocks previous close was at 8.46 this is indicating there is a potential upside of 245.7%. The day 50 moving average is 8.08 while the 200 day moving average is 8.13. The company has a market capitalisation of $181m. Find out more information at: http://www.heatbio.com
Heat Biologics, a biopharmaceutical company, focuses on developing immunotherapies to activate patient’s immune system against cancer through T-cell activation and expansion. The company’s T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company’s preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.